ReviewAAPS PharmSciTech2025
Exploring the Therapeutic Potential of Lipid Nanocarriers in Psoriasis Management: Advances and Applications.
Review in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ultra-deformable transethosomal vesicle for enhancing transdermal delivery of NSAIDs: a comprehensive review.Inflammopharmacology · 2026Review
- Shikonin-Loaded ROS-Responsive Microneedles for Psoriasis Therapy: Formulation, Transdermal Delivery, and Mechanistic Evaluation.Pharmaceutics · 2026Article
- Nanocarriers for Psoriasis Treatment: Insights from a Clinical Trial Registered on the Global Clinical Trials Registry Platform.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory skin disorder characterized by hyperproliferation of keratinocytes and immune dysregulation, leading to erythematous, scaly plaques. Conventional treatments, including corticosteroids, immunosuppressants, and biologics, often present challenges such as systemic side effects, poor skin penetration, and reduced patient compliance. Lipid nanocarriers (LNCs) have emerged as promising drug delivery systems for psoriasis management, offering enhanced drug stability, targeted delivery, improved skin penetration, and controlled drug release. This review explores the advancements in LNC-based formulations, including solid lipid nanoparticles, nanostructured lipid carriers, liposomes, and ethosomes, highlighting their advantages over traditional therapies. The physicochemical properties, mechanisms of skin penetration, and therapeutic efficacy of LNCs in psoriasis treatment are discussed, along with preclinical and clinical findings. The integration of lipid nanocarriers into psoriasis treatment regimens holds significant promise for improving patient outcomes by providing more effective and safer therapeutic alternatives.
Indexed as
Identifiers
40691409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.